A seasoned board member, CEO and venture capitalist, Mr. Schmitt has a 35-year track record of successfully building companies and commercializing complex, regulated life science technologies, primarily in collaboration with top tier universities and academic medical centers. He was named to the Bellrock Board in April 2017.
As a CEO, he has spearheaded the formation and growth of five companies (two public and three private). As a venture capitalist and CEO, he has raised over $500 million in growth capital financings and has led numerous transactions including IPOs, mergers, acquisitions, divestitures, licenses, and joint ventures.
Mr. Schmitt has been a Managing Director of Novitas Capital since 1999 and serves on the Boards of GelMed Sciences, JBS United Animal Health JV, Cernostics (Chairman) and as the Amorcyte shareholder representative to Caladrius (CLBS: NASDAQ).
He has been a member of the Board of Trustees of The Wistar Institute since 2002, having served as Chairman of the Intellectual Property Committee and as a member of the Executive Committee. Mr. Schmitt graduated with a BS in Finance from Lehigh University and an MBA from Rutgers University.